Equities research analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to post sales of $140.76 million for the current quarter, Zacks reports. Six analysts have made estimates for Medidata Solutions’ earnings, with the highest sales estimate coming in at $141.34 million and the lowest estimate coming in at $140.20 million. Medidata Solutions posted sales of $124.47 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 13.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, February 8th.

According to Zacks, analysts expect that Medidata Solutions will report full-year sales of $140.76 million for the current financial year, with estimates ranging from $544.50 million to $546.00 million. For the next fiscal year, analysts forecast that the company will report sales of $641.57 million per share, with estimates ranging from $635.19 million to $650.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The business had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same quarter in the prior year, the business posted $0.28 EPS. Medidata Solutions’s revenue for the quarter was up 16.7% compared to the same quarter last year.

MDSO has been the topic of a number of recent analyst reports. Royal Bank of Canada restated a “hold” rating and set a $80.00 price target on shares of Medidata Solutions in a research note on Friday, October 27th. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BidaskClub upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Deutsche Bank started coverage on shares of Medidata Solutions in a research note on Friday, December 8th. They issued a “buy” rating and a $78.00 price objective on the stock. Finally, TheStreet lowered shares of Medidata Solutions from a “b” rating to a “c+” rating in a research note on Thursday, December 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $84.54.

Medidata Solutions (NASDAQ MDSO) opened at $66.86 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. Medidata Solutions has a 52 week low of $47.77 and a 52 week high of $85.92. The stock has a market cap of $3,908.70, a P/E ratio of 95.52, a price-to-earnings-growth ratio of 3.46 and a beta of 1.69.

In related news, EVP Michael I. Otner sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total transaction of $708,800.00. Following the sale, the executive vice president now owns 80,674 shares in the company, valued at $5,718,173.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Tarek Sherif sold 200,000 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Insiders sold 239,010 shares of company stock worth $16,437,036 in the last quarter. Company insiders own 5.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in MDSO. Canada Pension Plan Investment Board grew its position in Medidata Solutions by 2,994.6% during the third quarter. Canada Pension Plan Investment Board now owns 1,151,200 shares of the company’s stock valued at $89,863,000 after buying an additional 1,114,000 shares during the period. American Century Companies Inc. grew its position in Medidata Solutions by 610.9% during the third quarter. American Century Companies Inc. now owns 1,186,843 shares of the company’s stock valued at $92,645,000 after buying an additional 1,019,883 shares during the period. Eagle Asset Management Inc. grew its position in Medidata Solutions by 292.9% during the third quarter. Eagle Asset Management Inc. now owns 835,286 shares of the company’s stock valued at $66,371,000 after buying an additional 622,694 shares during the period. State Street Corp grew its position in Medidata Solutions by 27.7% during the second quarter. State Street Corp now owns 1,828,913 shares of the company’s stock valued at $143,022,000 after buying an additional 396,793 shares during the period. Finally, Voya Investment Management LLC grew its position in Medidata Solutions by 1,571.0% during the second quarter. Voya Investment Management LLC now owns 376,259 shares of the company’s stock valued at $29,423,000 after buying an additional 353,742 shares during the period.

TRADEMARK VIOLATION NOTICE: “Medidata Solutions Inc (MDSO) Expected to Announce Quarterly Sales of $140.76 Million” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/01/22/medidata-solutions-inc-mdso-expected-to-announce-quarterly-sales-of-140-76-million-2.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.